PTEN Peptide
€100.00
In stock
SKU
350507
Protein Family: Enzymes
Pathway and Disease: Cancers, Carbohydrate Metabolism, Cell Communication, Cell Growth and Death, Signal Transduction
Alternate Names: Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; Phosphatase and tensin homolog; Mutated in multiple advanced cancers 1; MMAC1, TEP1
Accession No.: P60484, NP_000305
Description:
PTEN is a dual-specificity protein phosphatase, dephosphorylating tyrosine-, threonine- and serine-phosphorylated proteins. PTEN has also a lipid phosphatase activity that is critical for its tumor suppression function. PTEN antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. Defects in PTEN are the cause of numerous cancers such as in Cowden disease (breast, thyroid and skin cancer predisposition), Lhermitte-Duclos disease, and head and neck squamous cell carcinoma.
Format:
Each vial contains 0.1 mg of lyophilized peptide. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. Use at 5.6 ug/ml for a 100X excess over antibody for maximum blocking effect.
MW: 2243.4 g/mol
Sequence:
The synthetic peptide used to raise the antibody Cat. No. 200145 is selected from a sequence within the N-term region of human PTEN. For blocking experiments, a 10 to 100 fold molar excess to antibody is recommended.
Composition:
C94H151N31O31S1
Purity:
> 80% by HPLC
Solubility:
Distilled water for a solution up to 2 mg/ml, otherwise we recommend using acetonitrile.
Storage:
Store at -20°C. The product is hygroscopic and must be protected from light. Product is guaranteed one year from the date of shipment. Following reconstitution, store at -20°C.
Pathway and Disease: Cancers, Carbohydrate Metabolism, Cell Communication, Cell Growth and Death, Signal Transduction
Alternate Names: Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; Phosphatase and tensin homolog; Mutated in multiple advanced cancers 1; MMAC1, TEP1
Accession No.: P60484, NP_000305
Description:
PTEN is a dual-specificity protein phosphatase, dephosphorylating tyrosine-, threonine- and serine-phosphorylated proteins. PTEN has also a lipid phosphatase activity that is critical for its tumor suppression function. PTEN antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. Defects in PTEN are the cause of numerous cancers such as in Cowden disease (breast, thyroid and skin cancer predisposition), Lhermitte-Duclos disease, and head and neck squamous cell carcinoma.
Format:
Each vial contains 0.1 mg of lyophilized peptide. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. Use at 5.6 ug/ml for a 100X excess over antibody for maximum blocking effect.
MW: 2243.4 g/mol
Sequence:
The synthetic peptide used to raise the antibody Cat. No. 200145 is selected from a sequence within the N-term region of human PTEN. For blocking experiments, a 10 to 100 fold molar excess to antibody is recommended.
Composition:
C94H151N31O31S1
Purity:
> 80% by HPLC
Solubility:
Distilled water for a solution up to 2 mg/ml, otherwise we recommend using acetonitrile.
Storage:
Store at -20°C. The product is hygroscopic and must be protected from light. Product is guaranteed one year from the date of shipment. Following reconstitution, store at -20°C.
| Is Featured? | No |
|---|
Write Your Own Review